Navigation Links
Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine
Date:4/19/2013

ed risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. It's for topical ophthalmic use only, and not for injection.

Serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, some fatal and significant elevations in blood pressure have been reported. Caution is advised in pediatric patients less than five years of age, and in patients with elevated blood pressure, cardiovascular disease or hyperthyroidism. Blood pressure should be monitored in patients with cardiovascular or endocrine disease. Rebound miosis has been reported one day after instillation.

Ocular adverse reactions include eye pain and stinging on instillation, temporary blurred vision and photophobia. Cardiovascular adverse reactions include increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage.

About Paragon BioTeck, Inc.
Paragon BioTeck is a privately held ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight. For more information on the company and its work, visit http://www.paragonbioteck.com.

About Bausch + Lomb
Bausch + Lomb is a leading global eye health company that is solely focused on protecting, enhancing, and restoring people's eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. We globally develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries. Founded in 1853, our company is headquartered in Rochester, NY, and employs more than 11,000 people worldwide.

This release was i
'/>"/>

SOURCE Paragon BioTeck, Inc.; Bausch + Lomb
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
2. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
3. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
4. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
5. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
6. Agendia Signs Contract with Blue Shield of California
7. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
8. Volition Signs Collaboration Agreement With Abcodia
9. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
10. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
11. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2010 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix for ... today reported financial results for the third quarter ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO ...
... N.J., Nov. 4, 2010 PharmaNet Development Group, Inc., ... pharmaceutical, biotechnology, generic drug and medical device companies, today ... by Company scientists at the 2010 American Association of ... from November 14 -18 at the Ernest N. Morial ...
... seventeen Texas biotechnology companies were awarded more than $35 ... part of the Qualifying Therapeutic Discovery Project Tax Credit ... and the National Institutes of Health. "The ... the ability to continue to invest resources into their ...
Cached Biology Technology:Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 7PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 2PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 3Texas Biotech Firms Receive More Than $35 Million in Federal Grants and Credits 2Texas Biotech Firms Receive More Than $35 Million in Federal Grants and Credits 3
(Date:4/15/2014)... nanoparticle form could help reduce side effects by targeting ... scientists have developed nanoparticles that deliver one or two ... design particles that can carry any more than that ... devised a new way to build such nanoparticles, making ... drugs. In a paper published in the Journal ...
(Date:4/15/2014)... temperatures in the Congo Basin to increase by ... by greenhouse gases by half, according to a ... Belgium. , Explosive population growth and inefficient agricultural ... in Central Africa. A team of researchers from ... will affect longer-term temperatures in the region. Using ...
(Date:4/15/2014)... systems soon could be powering the forklifts used in ... with faster refueling times than ever before, courtesy of ... Carriers (HHC). , The goal of the project is ... refuel at low pressure four to five times faster ... hydrogen a competitive advantage over batteries for a big ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Study: Deforestation could intensify climate change in Congo Basin by half 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4
... intelligent prey such as monkeys which have exceptionally large ... The study, carried out by Dr Susanne Shultz, from ... Africa and South America such as the jaguar, chimpanzee, ... a small brain such as small antelope, mongooses and ...
... report that tumor cells display a dramatic reduction of ... to activate the expression of protective microRNAs in the ... issue of Cancer Cell, demonstrates that agents known to ... may function as tumor suppressors in normal cells and ...
... 90 years that cancer cells commonly display altered ... is not completely understood. Now, a new study ... reveals a functional connection between carbohydrate-driven energy production ... inhibition of a specific aspect of glucose metabolism ...
Cached Biology News:Activation of microRNA inhibits cancer gene in human cancer cells 2Researchers attack tumor cells by exploiting dependency on sugar metabolism 2
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: